Model-based cost-effectiveness analysis of atorvastatin drugs for prevention of cardiovascular diseases in Iran
Background: Today, cardiovascular disease is one of the main causes of mortality and disability in most developed and developing countries. The prediction of the major causes of deaths all over the world at all ages shows that 61% of deaths are due to chronic diseases, of which 30% is due to cardiov...
Main Authors: | Alireza Jabbari, Abdosaleh Jafari, Marziye Hadian, Mohammad Ghasemi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | International Journal of Preventive Medicine |
Subjects: | |
Online Access: | http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2020;volume=11;issue=1;spage=57;epage=57;aulast=Jabbari |
Similar Items
-
The cost-effectiveness and cost-utility of statin drug for the treatment of patients with cardiovascular disease, a systematic review
by: Mahmoud Eisavi, et al.
Published: (2021-01-01) -
Monacolin and atorvastatin in cardiovascular prevention – an attempt at positioning
by: Marcin Barylski
Published: (2017-03-01) -
Atorvastatin in the secondary prevention of cardiovascular diseases
by: N. A. Vaulin
Published: (2014-12-01) -
Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients
by: Yi-Cong Ye, et al.
Published: (2015-01-01) -
Effect of atorvastatin combine with aspirin on flammatory factors, endothelial function and the cardiovascular complications with diabetic patients
by: Hong Wang, et al.
Published: (2016-03-01)